Crossmark

A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab

Published Online: 2024-12-18

Authors

Zou, Ting

Li, Zhuoyang

Wang, Tianhong

Deng, Shuang

Wang, Siman

Hua, Yusi
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 12 September 2024

Accepted: 2 December 2024

First Online: 18 December 2024

Declarations

:

: The study used the public database which did not need ethics approval and consent to participate ().

: All authors consent to publish the article.

: The authors declare no competing interests.

Document is current